Maybe it happened when you woke up. Part of the view in one eye was just gone, like someone had smudged the top or bottom of the picture. It didn’t hurt. Your eye doctor called it NAION, and nobody asked about your Ozempic.
That question is getting asked now. On November 9, 2026, the FDA ordered every GLP-1 drug sold in the U.S. to add a warning about NAION, a rare optic nerve condition that can cause sudden, permanent vision loss. If you lost vision after taking one of these drugs, you may be able to join a GLP-1 RAs lawsuit. A free review can tell you where you stand.
What did the FDA just announce?
The FDA now requires drugmakers to add NAION to the Warnings and Precautions section of every GLP-1 label. That’s the part of the label doctors are supposed to read before they prescribe.
NAION stands for non-arteritic anterior ischemic optic neuropathy. In plain English, the blood flow to the optic nerve drops, and the nerve gets damaged. The nerve carries what your eye sees to your brain. When it’s damaged, the vision loss is usually painless, usually in one eye, and often permanent.
The FDA said NAION has been reported with every GLP-1 drug currently on the market. That’s why the warning applies across the whole class, not to one brand.
Can GLP-1 drugs cause vision problems?
The FDA says the risk is real but rare. It reviewed 126 studies covering more than 134,000 people. NAION showed up in about 6 out of every 100,000 GLP-1 users per year, compared with about 4 per 100,000 among people on a placebo or another diabetes drug.
Small numbers. But if you’re one of those six, the odds don’t matter much.
The FDA isn’t the first to raise this. A 2024 JAMA Ophthalmology study linked semaglutide, the drug in Ozempic and Wegovy, to a higher rate of NAION. In 2025, the European Medicines Agency listed NAION as a very rare side effect of semaglutide. The FDA’s own insurance-data review was mixed. It found a higher risk compared with one group of diabetes drugs but not another. That’s one reason the science will be argued over in court.
Which drugs does the warning cover?
All of them. GLP-1 RAs (short for GLP-1 receptor agonists) are prescribed for type 2 diabetes, weight loss, or both. The warning covers brands including:
- Ozempic
- Wegovy
- Rybelsus
- Mounjaro
- Zepbound
- Trulicity
- Saxenda
- Victoza
Generic exenatide and combination products that contain a GLP-1 are covered too.
Why does the new warning matter for a GLP-1 RAs lawsuit?
Because the people who lost vision before this month never got that warning.
The core claim in a GLP-1RA lawsuit is failure to warn. Plaintiffs argue the manufacturers, mainly Novo Nordisk and Eli Lilly, should have told patients and doctors about the NAION risk sooner. A warning added in late 2026 doesn’t help someone prescribed Ozempic in 2023 who lost sight in one eye the next year. Those patients made decisions without the full picture.
The companies dispute these claims, and no court has ruled on them yet. Still, a federal agency now says the risk belongs on the label, which is a meaningful development for these cases
Is there a GLP-1 class action?
Not technically. Most people searching for a GLP-1 class action are really looking for the federal multidistrict litigation, or MDL.
Here’s the difference. In a class action, one case speaks for everyone. In an MDL, each person keeps their own lawsuit, but the cases are grouped before one judge to handle evidence and pretrial rulings together. Your claim stays yours, and so does any compensation tied to your specific injuries.
The GLP-1 vision loss cases are consolidated in MDL 3163 in the U.S. District Court for the Eastern District of Pennsylvania, before Judge Karen S. Marston. It was created in December 2025. As of early November 2026, roughly 280 cases were pending. The case is in discovery, the stage where each side gathers evidence. There’s no settlement yet.
What should you do if you’ve had GLP-1 and eye issues?
If you suddenly lose vision in one eye, notice a blind spot, see a dark or blurry patch in the center of your vision, or colors look washed out, get to a doctor right away. The FDA says to seek care immediately, especially if it happens when you wake up.
Do not stop taking any prescribed medication without talking to your doctor first. A GLP-1 may be managing a serious condition, and that call belongs to you and your doctor.
Then, if you’ve already been diagnosed:
- Write down which GLP-1 you took and roughly when you started.
- Keep your eye doctor’s records, especially anything that says NAION or optic nerve damage.
- Talk to a GLP-1 lawyer before too much time passes. Filing deadlines vary by state, and waiting can cost you your claim.
For a deeper look at the litigation, see our full guide to the Ozempic blindness lawsuit.
Frequently Asked Questions
The FDA says they may. Its review of 126 studies found NAION was rare but showed up more often in GLP-1 users, about 6 cases per 100,000 people per year versus about 4 per 100,000 on other treatments. That’s why it issued a warning on every GLP-1 drug in November 2026.
Not on U.S. labels until the FDA stepped in. NAION wasn’t part of the U.S. warnings until the FDA required it in November 2026. Lawsuits claim the manufacturers should have warned sooner. The companies dispute that.
No, it’s an MDL, which works differently. Vision loss claims are grouped in MDL 3163 in federal court in Pennsylvania. Each person keeps an individual case, so your claim is valued on your own injuries rather than split across a class.
You may, if you took a GLP-1 and were later diagnosed with NAION, optic nerve damage, or sudden vision loss, and you don’t already have a lawyer for it. Every case is different, so a free review is the quickest way to know for sure.
You deserve to know if your vision loss was preventable.
Talk to Ethen Ostroff Law for a free GLP-1 vision loss review
If you or someone you love lost vision after taking a GLP-1, we’ll listen, look at what happened, and tell you honestly whether you may have a claim. The review is free, and there’s no pressure. You pay no fee unless we win. Start your free GLP-1 claim review or call us today. Justice For All.
